Research programme: anti-beta-amyloid antibodies - sanofi-aventis/Rockefeller University
Latest Information Update: 16 Jul 2016
At a glance
- Originator Rockefeller University
- Developer Sanofi
- Class Monoclonal antibodies
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Alzheimer's-disease in France (Parenteral)
- 03 Dec 2009 Early research in Alzheimer's disease in France (Parenteral)